What Dexcom Stelo’s Pediatric OTC Approval Changes
Dexcom Stelo is an over-the-counter continuous glucose monitor for children that combines a wearable sensor with an app to display glucose trends, giving families and caregivers a prescription-free way to track pediatric glucose patterns in real time. The FDA has cleared Stelo as the first OTC continuous glucose monitor for children 2 years and older who do not use insulin, including kids using oral diabetes medication or families tracking how food and activity affect glucose. Stelo uses a small wearable sensor that sends readings to a paired smartphone or smart device every 15 minutes, with each sensor lasting up to 15 days, though wear time may be shorter in children. Stelo does not provide low-glucose alerts and is not intended for children with problematic hypoglycemia or those on dialysis, so clinical guidance remains important before changing any medication or care plans.
Parental Oversight, App Access, and Data-Sharing Decisions
For parents, Stelo’s OTC status removes the prescription barrier but shifts the focus to app-based oversight. The system depends on a compatible smartphone or smart device, which may be the child’s phone, a caregiver’s phone, or both, raising questions about who sees glucose data and when. Glucose values and trends display every 15 minutes, making it possible for caregivers to monitor patterns and respond to concerning changes during the day. However, Stelo is not a standalone meter; if the phone is out of range, powered off, or incompatible with the app’s listed iOS or Android requirements, data will not update. Families must decide how to share login credentials, whether to install the app on multiple devices, and how to handle notifications without causing alarm or over-monitoring, especially when the child is away from home.
How Schools May Need to Adapt Policies for OTC CGM Kids
Stelo brings continuous glucose monitor children workflows straight into classrooms, where existing rules around phones and wearables may not fit. Because Stelo relies on a nearby smartphone or smart device, strict no-phone policies, limited Wi‑Fi, or device bans during tests could interrupt pediatric glucose monitoring during school hours. School IT and health staff will need to decide whether caregiver-connected phones can stay powered and nearby, and who should respond if glucose data suggest a problem when the child is at school. Policies may also need to address data privacy and notification boundaries: teachers and nurses may see more app-driven health requests without clear protocols. As wearable computing becomes more common, schools will have to align health accommodations, digital safety rules, and special education or medical plans so that OTC CGM kids can safely use Stelo without disrupting learning.
Insurance, Equity, and the Future of Pediatric Glucose Monitoring
Although Stelo’s OTC label can broaden access, insurance reimbursement for over-the-counter CGMs remains uncertain, creating a risk of unequal access to pediatric glucose monitoring. Benefits teams and insurers must decide whether Stelo counts as a covered medical device or a lifestyle tool, especially since it is cleared for people with diabetes on oral medications and for those tracking diet and exercise effects. According to the FDA, prediabetes is becoming more common among children, and the hope is that OTC CGM kids tools can raise awareness of how diet and activity shape glucose patterns. At the same time, some clinicians warn that there is limited data to define which glucose spikes matter in people with prediabetes or no diabetes, so coverage decisions may evolve slowly. Until clear reimbursement models emerge, families with better benefits or more disposable income are likely to have earlier access.
